Literature DB >> 24691993

VISTA is an immune checkpoint molecule for human T cells.

J Louise Lines1, Eirini Pantazi, Justin Mak, Lorenzo F Sempere, Li Wang, Samuel O'Connell, Sabrina Ceeraz, Arief A Suriawinata, Shaofeng Yan, Marc S Ernstoff, Randolph Noelle.   

Abstract

V-domain Ig suppressor of T cell activation (VISTA) is a potent negative regulator of T-cell function that is expressed on hematopoietic cells. VISTA levels are heightened within the tumor microenvironment, in which its blockade can enhance antitumor immune responses in mice. In humans, blockade of the related programmed cell death 1 (PD-1) pathway has shown great potential in clinical immunotherapy trials. Here, we report the structure of human VISTA and examine its function in lymphocyte negative regulation in cancer. VISTA is expressed predominantly within the hematopoietic compartment with highest expression within the myeloid lineage. VISTA-Ig suppressed proliferation of T cells but not B cells and blunted the production of T-cell cytokines and activation markers. Our results establish VISTA as a negative checkpoint regulator that suppresses T-cell activation, induces Foxp3 expression, and is highly expressed within the tumor microenvironment. By analogy to PD-1 and PD-L1 blockade, VISTA blockade may offer an immunotherapeutic strategy for human cancer. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24691993      PMCID: PMC3979527          DOI: 10.1158/0008-5472.CAN-13-1504

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

Review 1.  The B7 family revisited.

Authors:  Rebecca J Greenwald; Gordon J Freeman; Arlene H Sharpe
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

Review 2.  Transient intercellular adhesion: the importance of weak protein-protein interactions.

Authors:  P A van der Merwe; A N Barclay
Journal:  Trends Biochem Sci       Date:  1994-09       Impact factor: 13.807

Review 3.  Immunobiology of cancer therapies targeting CD137 and B7-H1/PD-1 cosignal pathways.

Authors:  Shengdian Wang; Lieping Chen
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

4.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

5.  B7 family molecules are favorably positioned at the human maternal-fetal interface.

Authors:  Margaret G Petroff; Lieping Chen; Teresa A Phillips; Dagmar Azzola; Peter Sedlmayr; Joan S Hunt
Journal:  Biol Reprod       Date:  2002-11-27       Impact factor: 4.285

6.  Phosphorylated immunoreceptor signaling motifs (ITAMs) exhibit unique abilities to bind and activate Lyn and Syk tyrosine kinases.

Authors:  S A Johnson; C M Pleiman; L Pao; J Schneringer; K Hippen; J C Cambier
Journal:  J Immunol       Date:  1995-11-15       Impact factor: 5.422

7.  A theory of self-nonself discrimination.

Authors:  P Bretscher; M Cohn
Journal:  Science       Date:  1970-09-11       Impact factor: 47.728

8.  Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.

Authors:  Manish J Butte; Mary E Keir; Theresa B Phamduy; Arlene H Sharpe; Gordon J Freeman
Journal:  Immunity       Date:  2007-07-12       Impact factor: 31.745

9.  Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials.

Authors:  J D Wolchok; J S Weber; M Maio; B Neyns; K Harmankaya; K Chin; L Cykowski; V de Pril; R Humphrey; C Lebbé
Journal:  Ann Oncol       Date:  2013-05-10       Impact factor: 32.976

Review 10.  New insights into the regulation of T cells by gamma(c) family cytokines.

Authors:  Yrina Rochman; Rosanne Spolski; Warren J Leonard
Journal:  Nat Rev Immunol       Date:  2009-07       Impact factor: 53.106

View more
  174 in total

1.  Comprehensive landscape of immune-checkpoints uncovered in clear cell renal cell carcinoma reveals new and emerging therapeutic targets.

Authors:  Mathilde Sautreuil; Mahmoud Bentriou; Diana Tronik-Le Roux; Jérôme Vérine; Maria Belén Palma; Marina Daouya; Fatiha Bouhidel; Sarah Lemler; Joel LeMaoult; François Desgrandchamps; Paul-Henry Cournède; Edgardo D Carosella
Journal:  Cancer Immunol Immunother       Date:  2020-03-12       Impact factor: 6.968

Review 2.  Checkpoint Inhibitors: Applications for Autoimmunity.

Authors:  Anna S Tocheva; Adam Mor
Journal:  Curr Allergy Asthma Rep       Date:  2017-09-27       Impact factor: 4.806

Review 3.  Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential.

Authors:  Gregory T Wurz; Chiao-Jung Kao; Michael W DeGregorio
Journal:  Ther Adv Med Oncol       Date:  2016-01       Impact factor: 8.168

4.  DNA methylation of immune checkpoints in the peripheral blood of breast and colorectal cancer patients.

Authors:  Asma A Elashi; Varun Sasidharan Nair; Rowaida Z Taha; Hibah Shaath; Eyad Elkord
Journal:  Oncoimmunology       Date:  2018-11-10       Impact factor: 8.110

5.  VISTA deficiency attenuates antibody-induced arthritis and alters macrophage gene expression in response to simulated immune complexes.

Authors:  Sabrina Ceeraz; Susan K Eszterhas; Petra A Sergent; David A Armstrong; Alix Ashare; Thomas Broughton; Li Wang; Dov Pechenick; Christopher M Burns; Randolph J Noelle; Matthew P Vincenti; Roy A Fava
Journal:  Arthritis Res Ther       Date:  2017-12-08       Impact factor: 5.156

6.  Mechanistic Assessment of PD-1H Coinhibitory Receptor-Induced T Cell Tolerance to Allogeneic Antigens.

Authors:  Dallas B Flies; Tomoe Higuchi; Lieping Chen
Journal:  J Immunol       Date:  2015-04-27       Impact factor: 5.422

7.  CXCL17 Chemokine-Dependent Mobilization of CXCR8+CD8+ Effector Memory and Tissue-Resident Memory T Cells in the Vaginal Mucosa Is Associated with Protection against Genital Herpes.

Authors:  Ruchi Srivastava; Marcela Hernández-Ruiz; Arif A Khan; Mona A Fouladi; Grace J Kim; Vincent T Ly; Taikun Yamada; Cynthia Lam; Sheilouise A B Sarain; Undariya Boldbaatar; Albert Zlotnik; Elmostafa Bahraoui; Lbachir BenMohamed
Journal:  J Immunol       Date:  2018-03-16       Impact factor: 5.422

Review 8.  Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.

Authors:  Frank A Schildberg; Sarah R Klein; Gordon J Freeman; Arlene H Sharpe
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

9.  Selective Involvement of the Checkpoint Regulator VISTA in Suppression of B-Cell, but Not T-Cell, Responsiveness by Monocytic Myeloid-Derived Suppressor Cells from Mice Infected with an Immunodeficiency-Causing Retrovirus.

Authors:  Kathy A Green; Li Wang; Randolph J Noelle; William R Green
Journal:  J Virol       Date:  2015-07-08       Impact factor: 5.103

Review 10.  The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation.

Authors:  Wenwen Xu; TạMinh Hiếu; Subramaniam Malarkannan; Li Wang
Journal:  Cell Mol Immunol       Date:  2018-01-29       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.